Viking starts oral obesity trial as Truist lifts target
Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash
Viking Therapeutics has begun an oral obesity trial for VK2735, testing maintenance dosing after initial weight loss. The study complements the company's existing injectable version and aims to broaden obesity treatment options. Separately, Truist Securities raised its price target on the stock to $87.00 from $83.00, citing optimism while acknowledging clinical execution risks common to development-stage biotechnology companies.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.